Pfizer's cardiomyopathy drug Vyndamax Cap and Roche's multiple sclerosis drug Ocrevus Inj are undergoing drug price negotiations with the National Health Insurance Service (NHIS) in Korea. Therefore, it will be interesting to see if the drugs will be able to finalize negotiations and their reimbursement listing agenda be submitted to the Health Insurance Policy Review Committee in January.

According to industry sources on the 2nd, the NHIS recently added Ocrevus Inj (ocrelizumab) and Vyndamax Cap 61 mg (tapamidis) to the list of drugs subject to drug price negotiations.

Ocrevus Inj was deliberated to be adequate for reimbursment at the 11th Drug Reimbursment Evaluation Committee